Hans van der Meer
University of Amsterdam, Netherlands.

Abstract:

The CRISPR technology marks the start of genetic engineering revolution by providing precise DNA modification capabilities for healthcare and agricultural and biotechnology industries to develop broadly. Gene therapy built using CRISPR has generated substantial investment from pharmaceutical firms to research medical conditions covering sickle cell anemia and cystic fibrosis as well as particular cancers. CRISPR-modified crops show enhanced efficiency while getting better protected from diseases and possessing nutritional value that strengthens worldwide food availability by needing lower pesticide usage. CRISPR facilitates the progression of synthetic biology where scientists create biofuels and fake meat and generate genetically modified probiotics. CRISPR technology faces significant regulatory along with ethical complications in its present commercial application which require careful scrutiny. The ethical practice of modifying inheritable human genes presents major concerns because it creates unknown genetic issues and provide scientific opportunities for breeding selection while creating economic disparities based on gene modification status between different groups. The commercial applications of CRISPR technology focus on creating medical diagnoses that prevent death and establishing agricultural methods that promote sustainability and industrial operational efficiency. The immediate solution of CRISPR ethical problems and regulatory constraints is crucial to prevent discriminatory social consequences and negative side reactions. Global cooperation with ethical regulations and equal access enables CRISPR to become a transformative force which brings positive developments across multiple industrial sectors. Recognized governance of CRISPR will establish it as a modern technology for medical advancement within agriculture and biotechnology by securing ethical practices and resource welfare.